Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride ...
Intravenous amisulpride is indicated in adults for the prevention of postoperative nausea and vomiting, either alone or in combination with an antiemetic of a different class. It is also indicated for the treatment of postoperative nausea and vomiting in patients who have received anti-emetic prophylaxis with an agent of a different class or have not receive...
Geha Mental Health Center, Petach-Tikva, Israel
Stavanger University Hospital, Stavanger, Norway
Medizinische Universität Innsbruck, Innsbruck, Austria
Haukeland University Hospital, Bergen, Norway
McLean Hospital, Belmont, Massachusetts, United States
Imperial College London, London, United Kingdom
University College London, London, United Kingdom
University of Manchester, Manchester, United Kingdom
Chonbuk national university hospital, Jeonju, Korea, Republic of
Central Institute of Mental Health, Mannheim, Germany
Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup, Glostrup, Denmark
Yu-Li Hospital, Yu-Li, Hualien County, Taiwan
Yu-Li Veterans Hospital, Yu-Li, Hualien County, Taiwan
National Taiwan University Hospital, Taipei, Taiwan
Yu-Li Veternas Hospital, Hualien, Taiwan
University of Cologne, Dept. of Psychiatry and Psychotherapy, Cologne, NRW, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.